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SUMMARY
We report detailed susceptibility profiling of asexual
blood stages of the malaria parasite Plasmodium
falciparum to clinical and experimental antimalarials,
combined with metabolomic fingerprinting. Results
revealed a variety of stage-specific and metabolic
profiles that differentiated the modes of action of
clinical antimalarials including chloroquine, pipera-
quine, lumefantrine, and mefloquine, and identified
late trophozoite-specific peak activity and stage-
specific biphasic dose-responses for the mitochon-
drial inhibitors DSM265 and atovaquone. We also
identified experimental antimalarials hitting previ-
ously unexplored druggable pathways as reflected
by their unique stage specificity and/or metabolic
profiles. These included several ring-active com-
pounds, ones affecting hemoglobin catabolism
through distinct pathways, and mitochondrial inhibi-
tors with lower propensities for resistance than either
DSM265 or atovaquone. This approach, also appli-
cable to other microbes that undergo multiple differ-
entiation steps, provides an effective tool to prioritize
compounds for further development within the
context of combination therapies.
INTRODUCTION
Malaria caused by the protozoan parasite Plasmodium falcipa-
rum (Pf) remains a major public health menace, especially in
young children in sub-Saharan Africa (WHO, 2018). When an in-
dividual is bitten by a Plasmodium-infected mosquito, the para-
site first replicates in hepatocytes and then initiates48-h cycles
of red blood cell (RBC) infection. In these RBCs, the parasite de-
velops inside a parasitophorous vacuole, progressing from a ring
into a highly metabolically active trophozoite and then a multinu-
cleated schizont that yields 8–24 merozoites generated through
asexual replication. Upon egress from the lysed host RBC, these
merozoites infect new RBCs, with parasites capable of infecting
up to 10%–20% of RBCs in an immunologically naive host (Phil-
lips et al., 2017).
Chemotherapy remains a major pillar in the fight against
malaria, alongside vector control, diagnosis, and access to
treatment. The former first-line antimalarials chloroquine and
sulfadoxine-pyrimethamine mainly affect trophozoites by inhibit-
ing the hemoglobin catabolism pathway that provides nutrients
for the parasite and the folate biosynthesis pathway that
delivers the building blocks for DNA synthesis, respectively
(Blasco et al., 2017). KAI407, a phosphatidylinositol 4-kinase
(PI4K) inhibitor, is one of the more recent candidate antimalarials
that specifically inhibit schizont development (McNamara et al.,
2013). These drugs mostly target trophozoites and schizonts,
which sequester in the microvasculature (Miller et al., 2002).
Compounds targeting ring stages, which circulate throughout
the blood stream, are desirable to prevent further vasculature
blockage. Artemisinins were the first clinical antimalarials with
ring-stage activity, and artemisinin-based combination therapies
have proven effective in reducing malaria death and case load
(WHO, 2018). However, parasites resistant to artemisinins and
their partner drugs have emerged and are now undermining ma-
laria control (Menard and Dondorp, 2017; Ross and Fidock,
2019). The discovery of antimalarials that hit novel targets and
are active against multiple asexual blood stages, including rings,
is thus of paramount importance.
Thousands of antimalarials with submicromolar potency have
been identified in high-throughput whole-cell screens (Anto-
nova-Koch et al., 2018; Delves et al., 2018; Gamo et al., 2010;
Guiguemde et al., 2010; Plouffe et al., 2008; Raphemot et al.,
2015; Wu et al., 2015), but target identification forms a major
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bottleneck for their further development into leads with
increased target binding, selectivity, and whole-cell activity
(Okombo and Chibale, 2017). Metabolomic analysis of biochem-
ical pathways affected upon compound exposure recently
identified the mode of action of various candidate antimalarials
from the Medicines for Malaria Venture Malaria Box (Allman
et al., 2016), and is a valuable tool to interrogate new screening
hits. Combining this approach with other phenotypic assays can
help explore the activity profile and therapeutic potential of
candidate antimalarials.
The Malaria Drug Accelerator (MalDA) consortium aims to
identify new antimalarial leads through in vitro phenotypic
screens and the identification of novel assayable targets (Anto-
nova-Koch et al., 2018; Cowell et al., 2018). Within this context,
we developed an assay that compares the stage-specific sus-
ceptibility of Pf asexual blood stage parasites and combined
this with metabolomic profiling.
RESULTS
We designed a medium-throughput in vitro assay to quantita-
tively assess the susceptibility of the distinct stages of Pf
intra-erythrocytic development. Highly synchronized 3D7-A10
parasites (that have an accelerated 40-h asexual blood stage cy-
cle) were exposed to a range of compound concentrations for 8 h
during the early ring, late ring, early trophozoite, late trophozoite,
and schizont stages (Figure 1A). Assays were performed in 96-
well plates, with a maximum in-well DMSO concentration of
0.35%. Cultures were continued to allow parasites to further
develop in the absence of compound, extending through to inva-
sion of new RBCs and development until the trophozoite stage.
The total assay duration was 60 h. Parasites were stained with
SYBR green and Mitotracker Deep Red and quantified by flow
cytometry. Half-maximal inhibitory concentrations (IC50) were
derived by non-linear regression analyses of the dose-response
data. The IC50 value based on these 8-h exposures at specific
asexual blood stages is referred to as the IC50
8h, while the IC50
calculated from the standard 72-h exposure assay is the IC50
72h.
Light microscopy confirmed that the different periods of expo-
sure corresponded to the different developmental stages and
showed that the 32- to 40-h time point spanned schizont devel-
opment, parasite egress, and reinvasion (Figure 1A), indicating
that all asexual blood stages were profiled. The assay was
further validated by the stage-specific susceptibility profiles of
dihydroartemisinin, chloroquine, and KAI407, which showed
the expected peak activity on early rings, rings and trophozoites,
and schizonts, respectively (Blasco et al., 2017; Zhang et al.,
1986) (Figure 1B). The 35-fold difference in IC50
8h between schiz-
onts and late trophozoites for KAI407 (Table S1) highlighted the
tight synchronization of parasites that is crucial for this assay.
The asexual blood stage susceptibility profile was determined
for a set of 36 compounds that included licensed drugs, candi-
date antimalarials, compounds with a known target, and various
screening hits (profiles of compounds are shown in Figures 2, 3,
4, and 5, simplified molecular input line entry system descrip-
tions for compounds are listed in Table S2, and structures of
compounds are displayed in Figures S1 and S2). Hits were
selected from screens previously performed by the MalDA con-
sortium (see Table S2 references) and prioritized based on their
potency, chemical diversity, and unknown mode of action.
Licensed antimalarial drugs and additional previously published
preclinical compounds were included to provide more insights
into their mode of action or to serve as a reference.
First, compoundswere classified based on their timing of peak
activity, defined as the asexual blood stage at which the com-
pounds showed the lowest IC50
8h values. This identified com-
pounds with peak activity during (1) all rings and trophozoites,
(2) all rings, (3) all trophozoites, (4) all trophozoites and schizonts,
(5) late trophozoites, and (6) schizonts (Figure 6). When com-
pounds were classified by their overall activity profile based on
identifying the specific stages that showed IC50
8h values
<1 mM (Figure S3; Table S1), seven active classes were identi-
fied: compounds active on (1) all asexual blood stages, (2) all
rings and trophozoites, (3) late rings and all trophozoites, (4) all
trophozoites and schizonts, (5) late trophozoites and schizonts,
(6) only late trophozoites, and (7) only schizonts. Fosmidomycin,
a moderately potent inhibitor of Pf isoprenoid biosynthesis (Jo-
maa et al., 1999), as well as the hit compounds MMV000787,
MMV019017, MMV020746, MMV022478, and MMV665939,
showed IC50
8h values >1 mM at all tested stages and therefore
did not match any of these groups (Table S1).
The clinical antimalarials dihydroartemisinin, chloroquine, pi-
peraquine, and lumefantrine showed little variation in IC50
8h
values throughout the ring and trophozoite stages, and were
consequently classified in the group with peak activity at ring
and trophozoite stages. Although chloroquine, piperaquine,
and lumefantrine IC50
8h values were similar for ring and tropho-
zoite stages, survival curves for early rings were less steep
than those for late rings and trophozoites (Figures 1 and 2).
DSM265 and atovaquone, which are inhibitors of pyrimidine syn-
thesis and the mitochondrial electron transport chain, respec-
tively (Figure 5A), showed peak activity specifically during late
trophozoite stages (Figures 5B and 6). These mitochondrial in-
hibitors also displayed a biphasic survival curve at the early
trophozoite and schizont stages that was not observed at other
stages (Figure 5B; Table S1).
MMV000442, MMV006455, MMV007181, and MMV665971
showed incomplete killing at all asexual blood stages, with evi-
dence of initial growth inhibition at lower concentrations followed
by demonstrably better growth at higher concentrations in the
early and late ring stages (Figures 3 and 4). This incomplete
killing was not observed in the 72-h exposure survival curves
for these compounds (Figures 3 and 4). Aqueous solubility ex-
periments for MMV000442, MMV006455, and MMV007181 indi-
cated a solubility >100 mM (Table S3), well above the highest
concentration used in the stage specificity assay.
Figure 1. Experimental Design for Asexual Blood Stage Specificity Profiling of Antimalarials and Profiles of Reference Drugs
(A) Synchronized parasites were exposed for 8 h at the stages indicated. Survival at 60 h post-invasion was assessed by flow cytometry.
(B) Unique stage specificity profiles of chloroquine, dihydroartemisinin, and KAI407. Bar plots indicate the IC50
8h when parasites were exposed only during the
early ring, late ring, early trophozoite, late trophozoite, or schizont stage, with error bars showing the standard error of the mean based on at least three inde-
pendent repeats. KAI407, a PI4K inhibitor. All data are available in Table S1.
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To further examine whether the compound stage specificity
profiles that we identified correlated with their mode of action,
we examined the metabolic profile of 33 compounds (Fig-
ure 7; Table S4). These consisted of 27 newly assayed com-
pounds, plus another 6 (chloroquine, DSM265, MMV000248,
MMV006455, MMV019017, and KAE609) for which data were
already available (Allman et al., 2016). In these experiments,
we exposed trophozoite-infected RBCs to 103 IC50
72h concen-
trations and then subjected parasite extracts to mass spectrom-
etry-based metabolomic profiling (Allman et al., 2016).
Across all 33 compounds, we obtained quantitative data for
195 metabolites that represent major metabolic pathways,
including but not limited to pyrimidine and purine synthesis,
hemoglobin catabolism, folate biosynthesis, central carbon
Figure 2. Detailed Asexual Blood Stage Susceptibility Profiles for Antimalarials with Peak Activity on All Rings or All Rings and Trophozoites
Data for chloroquine and dihydroartemisinin can be found in Figure 1. Bar graphs indicate mean IC50
8h values, whereas survival graphs show the most repre-
sentative curves from independent repeats. Error bars indicate the standard error of the mean based on >3 independent repeats. Data are summarized in
Table S1.
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metabolism, glycolysis, and redoxmetabolism (Table S4). Based
on these metabolic profiles, compounds were hierarchically
clustered via Ward clustering based on Pearson correlation co-
efficients to identify related metabolic signatures (Figure 7).
Several established metabolic signatures were observed
among the analyzed compounds. Mitochondrial electron trans-
port chain disruption is linked to inhibition of dihydroorotate de-
hydrogenase (DHODH) and cytochrome bc1 (CytBC1), leading
to increases in the pyrimidine precursors dihydroorotate and
N-carbamoyl-L-aspartate (Allman et al., 2016). This metabolic
signature was observed for DSM265 and ATQ, which respec-
tively inhibit DHODH and CytBC1, as well as MMV000787,
MMV021735, and MMV030666, for which the mode of action
was previously unknown (Figure 7; Table S4).
We performed resistance selections with MMV021735,
MMV030666, and MMV000787 to compare their propensity for
resistance with that of DSM265 and atovaquone, which have a
relatively low minimum inoculum for resistance of 2 3 106 and
Figure 3. Detailed Asexual Blood Stage Susceptibility Profiles for Antimalarials with Peak Activity on All Trophozoites
Bar graphs indicatemean IC50
8h values, whereas survival graphs show themost representative curves from independent repeats. Error bars indicate the standard
error of the mean based on >3 independent repeats. Data are summarized in Table S1.
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23 107parasites, respectively, when using 33 IC50
72h drug con-
centrations (Phillips et al., 2015). Selections involving continuous
exposure of 13 109 Dd2-B2 parasites to a 3.53 IC50
72h concen-
tration of MMV000787, or intermittent drug pulsing in which
parasites were exposed for several days at a time to 6 3
IC50
72h concentrations of MMV000787 for 5 months, did not
result in MMV000787-resistant parasites. For MMV021735,
exposing 5 3 108 3D7-A10 parasites to 3 3 IC50
72h concentra-
tions in triplicate failed to yield resistant parasites. Exposing
5 3 108 3D7-A10 or Dd2-B2 parasites to 33 IC50
72h concentra-
tions of MMV030666 also failed to yield resistance. A ramping
selection with 3D7-A10 parasites starting at 1 3 IC50
72h and
Figure 4. Detailed Asexual Blood Stage Susceptibility Profiles for Antimalarials with Peak Activity on Late Trophozoites, or on All Trophozo-
ites and Schizonts
Data for DSM265 and atovaquone, both compounds with peak activity at the late trophozoite stage, can be found in Figure 5. Bar graphs indicate mean IC50
8h
values, whereas survival graphs show the most representative curves from independent repeats. Error bars indicate the standard error of the mean based on >3
independent repeats. Data are summarized in Table S1.
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gradually increasing to 1.83 IC50
72h over the course of 3 months
also did not produce resistance. These data indicate that
MMV000787, MMV21735, and MMV030666 have minimum
inocula of resistance well above 5 3 108 parasites.
Peptide decreases commonly linkedwith inhibition of hemoglo-
bin endocytosis and/or catabolism within the digestive vacuole
were also observed across multiple antimalarial compounds (Fig-
ure 7; Table S4). This metabolic signature of decreased peptide
levels (HVDD, PVNF, PEEK, PEE, DLS, SDL, SID, DLH, LD, PE,
PD, SD, VD, and EV) was particularly pronounced for the com-
pounds MMV022478, MMV019555, MMV667491, MMV030666,
MMV000248, MMV006455, MMV007181, MMV000442, GNF-
Pf-5660, KAE609, and MMV019017. Of these, MMV006455,
MMV019017, and KAE609 also possessed increased levels
of the deoxyribonucleotides dAMP and dTMP and decreased
levels of cAMP. KAE609, and MMV019017 also showed
decreased nucleoside di- and tri-phosphate levels (GDP,
UDP, GTP, dATP, dGTP/ATP, and dUTP), which have
previously been identified as a signature of inhibiting the Na+/
H+-dependent ATPase PfATP4 (Allman et al., 2016). The
hemozoin inhibitor chloroquine did not show the expected
strong hemoglobin catabolism signature, but instead showed
a more modest decrease in peptide levels and clustered with
the PfATP4-inhibitor KAE609.
Interestingly, the metabolic profile for MMV030666 indicated
perturbation of both the mitochondrial electron transport chain
and hemoglobin catabolism. MMV022224 induced increased
levels of peptides, a profile that has not been observed before.
Because of the peculiar profiles of these compounds, they
were selected for an additional study in which synchronized par-
asites were exposed to 33 the IC50
8h of the most sensitive life
stage at 8-h intervals, similar to the stage specificity assay,
and cell morphology was assessed by microscopy at the end
of each interval (Figure S4). This showed MMV030666-exposed
Figure 5. Late Trophozoites Are the Most
Susceptible Stage to DSM265 and Atova-
quone that Inhibit Pyrimidine Biosynthesis
and the Mitochondrial Electron Transport
Chain, Respectively
(A) Overview of the pyrimidine biosynthesis and the
mitochondrial electron transport chain pathways.
DSM265 inhibits DHODH, whereas atovaquone in-
hibits cytochrome bc1 (Goodman et al., 2017).
(B) Stage specificity profiles for DSM265 and ato-
vaquone. IC50
8h values for (B) are available in Ta-
ble S1.
parasites to be most susceptible during
the late trophozoite stage, as demon-
strated by their bloated digestive vacuoles.
This phenotype is characteristic of hemo-
globin catabolism perturbation (Ross
et al., 2018), and is consistent with the me-
tabolomics data. MMV022224-exposed
parasites proved to be affected mostly
during early and late trophozoite stages,
without displaying swollen vacuoles. The
health of ring-stage parasites, which
showed similar IC50
8h values as trophozoites for MMV022224,
was harder to microscopically evaluate due to their smaller size.
Mefloquine, naphthoquine, piperaquine, methylene blue,
MMV675939, dihydroartemisinin, WLL-vs, MMV668311, ferro-
quine, and MMV085071 did not induce major changes within
the set of metabolites detected in our study and, therefore, clus-
tered in the low fold change group (Figure 7; Table S4).
DISCUSSION
Herein we report the results of Pf asexual blood stage suscepti-
bility assays that compared the susceptibility of early rings, late
rings, early trophozoites, late trophozoites, and schizonts, for a
set of 36 clinical and experimental antimalarials. These studies,
which exposed each tightly synchronized stage for 8 h and as-
sessed overall parasite growth at the same 60-h time point (Fig-
ure 1A), extend earlier experimental designs that assessed activ-
ity on a subset of stages or did not include wash-offs to restrict
exposure to each stage (Duffy and Avery, 2017; Wilson et al.,
2013). Because compounds are washed out after each exposure
moment and parasites are allowed to continue to grow in
absence of compound until the end of the assay, the stage spec-
ificity assay quantifies the cytotoxic (killing) effect of compounds.
The IC50
8h values are therefore in essence stage-specific half
maximal lethal doses (Paguio et al., 2011). This contrasts with
the IC50
72h values that are determined in assays that expose par-
asites continuously to compounds and measure the cytostatic
(growth inhibitory) effect of compounds. Our results were com-
bined with metabolomic profiling of the cellular pathway pertur-
bations caused by these compounds, as an exploratory
approach to identify common or unique profiles among the
tested antimalarials. Classification of compounds according to
the timing of their peak activity revealed a remarkable variety
of profiles among both clinical and experimental compounds
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(Figure 6). As examples, the inhibitors DSM265 and atovaquone
(which target DHODH and CytBC1, respectively) showed activity
against late trophozoites only, and the PI4K inhibitor KAI407
showed activity against only schizonts, in good agreement with
earlier studies (McNamara et al., 2013; Painter et al., 2010; Phil-
lips et al., 2015) (Figures 1 and 5; Table S1).
Compounds with different chemical scaffolds that are known
to target the same or related pathways showed similar stage
specificity and metabolic profiles. This was especially apparent
for atovaquone and DSM265 that act on related mitochondrial
processes (Figure 5A). These agents also shared similar killing
dynamics, with a monophasic survival curve for the highly sensi-
tive late trophozoites and biphasic curves for early trophozoites
and schizonts (Figure 5B). Of note, when parasite survival was
assessed using only the SYBR green signal, and not the Mito-
tracker signal, we observed the same killing dynamics for atova-
quone and DSM265. This likely reflects a dual purpose of the
mitochondria of maintaining their membrane potential through
the mitochondrial electron transport chain, required for the pro-
duction of ATP, and enabling pyrimidine biosynthesis through
DHODH (Figure 5A). Inhibition of DHODH by DSM265 will not
only affect pyrimidine biosynthesis but also the recycling of ubi-
quinone, which is crucial for the parasite to maintain its mito-
chondrial membrane potential. Likewise, inhibition of CytB by
atovaquone will not only directly affect the mitochondrial mem-
brane potential, but also the recycling of ubiquinone and there-
fore the function of DHODH. DHODH and CytB are thus two
distinct drug targets that are functionally linked. In accordance,
DSM265 and atovaquone show the same stage specificity pro-
file. Pyrimidines are most needed in late trophozoites when
DNA synthesis peaks, allowing the production of daughter
merozoites during schizogony (Cassera et al., 2011). Without py-
rimidines, late trophozoites would not be able to develop into
functional schizonts, resulting in a low IC50
8h and a smooth
monophasic killing curve in late trophozoites (Figure 5B). In early
trophozoites and schizonts, the dependency on pyrimidines is
lower but a functional mitochondrial membrane potential would
still appear to be vital for themany ongoing biological processes,
leading to a biphasic response in which the first shift relates to
pyrimidine biosynthesis and a second shift relates to the mito-
chondrial membrane potential. Early and late rings showed a
monophasic response with high IC50
8h values, reflecting a para-
site growth phase when pyrimidine biosynthesis and mitochon-
drial activity appear to be minimal. Atovaquone inhibition
through membrane potential disruption was relatively ineffective
in our 8-h exposure model, illustrating the need for longer com-
pound exposure for mitochondrial electron transport chain
inhibitors (Gomez-Lorenzo et al., 2018; Painter et al., 2010).
Importantly, incomplete killing by atovaquone and DSM265
was observed in all stages, matching previous data from recru-
descence-based assays that showed atovaquone to be a slow
and incomplete killer (Linares et al., 2015; Sanz et al., 2012).
Of note, the late trophozoite stage specificity profiles for ATQ
and DSM265 are consistent with the timing of expression of their
targets: cytb expression peaks during the late trophozoite stage,
whereas maximal expression of dhodh spans early to late
trophozoite stages (Painter et al., 2018). The same holds true
for KAE609, which targets PfATP4: transcription of pfatp4 peaks
at the early trophozoite stage (Painter et al., 2018), consistent
with KAE609 being inactive against rings yet active against early
trophozoites and later stages. Interestingly, pi4k, which encodes
the target of KAI407, is transcribed at fairly stable levels without
showing a clear peak at any stage (Painter et al., 2018). The
schizont-specific activity profile of KAI407 may be determined
by the availability of substrates that interact at this stage
with PI4K.
These assays also differentiated the mode of action of chloro-
quine, piperaquine, and mefloquine, which share a core 4-ami-
noquinoline ring structure. Piperaquine essentially consists of
two molecules of chloroquine connected by a central linker.
Chloroquine and piperaquine are generally thought to act at
the highly metabolically active trophozoite stage by inhibiting
Figure 6. Stage of Peak Activity for Clinical and Experimental Antimalarials
Peak activity illustrates the period when the parasite was most susceptible to the tested compounds. MMV020746 andMMV665939 were omitted as their IC50
8h
values were >10 mM. All data are available in Table S1 and Figures 1, 2, 3, 4, and 5. ATQ, atovaquone; CQ, chloroquine; DHA, dihydroartemisinin; FQ, ferroquine;
LMF, lumefantrine; MB, methylene blue; MQ, mefloquine; NQ, naphthoquine; PPQ, piperaquine.
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the biomineralization of free heme, released during hemoglobin
digestion, into hemozoin, thereby causing a buildup of toxic
free heme or heme-drug adducts (Blasco et al., 2017). Both chlo-
roquine and piperaquine showed a similar stage specificity pro-
file when the error margin is taken into account, and exerted
potent growth inhibition in early ring stages. This would suggest
that hemoglobin catabolism begins even in early rings, before
the formation of the digestive vacuole inside which the bulk of
hemozoin is generated. This inference is supported by a previous
report (Zhang et al., 1986) and studies that detected hemoglobin
uptake (Elliott et al., 2008) and activity of falcipains (required
for hemoglobin digestion [Xie et al., 2016]) in very early rings.
Notably, early rings showed a flatter slope of the dose-depen-
dent curve than late rings and trophozoites, indicating different
growth inhibitory dynamics (Figures 1 and 2). Metabolic pertur-
bation profiles, nonetheless, revealed a strikingly different profile
for chloroquine and piperaquine (Figure 7; Table S4). Chloro-
quine induced various perturbations that were not observed
under piperaquine pressure, such as >2-fold increased levels
of dAMP, dUTP, cytidine, xanthosine, and N-acetyl-lysine,
decreased p-hydroxybenzoate levels, and decreased peptide
levels that are characteristic for hemoglobin catabolism inhibi-
tion. Some of these metabolic changes in chloroquine-exposed
parasites, such as the increased dAMP levels, caused chloro-
quine to metabolically cluster with the PfATP4 inhibitor KAE609
and other compounds that cause an overall disturbance in
cellular homeostasis. This clustering, however, is based on
rather modest changes and should be interpreted with caution.
Piperaquine metabolically clustered with other compounds
that induced an overall low differential fold change (Figure 7;
Table S4). The only notable changes were R2-fold decreased
levels of dCDP, dTMP, guanosine, and guanine. This suggests
that piperaquine might have an additional mode of action
beyond inhibition of hemozoin formation that perturbs purine
and pyrimidine metabolism.
Mefloquine, an arylamino alcohol that also shares a quinoline
ring, was earlier reported to inhibit hemozoin formation in para-
sites at a lower level than chloroquine (Combrinck et al., 2013),
possibly because of reduced mefloquine accumulation in the











































































































































































































































































































Figure 7. Metabolic Profiling of Compounds Identified Cellular Processes Targeted by Compounds
Compounds were clustered based on hydrophilic metabolite response to all measured metabolites (all data available in Table S4). Compounds are listed only if
they showed a >2-fold change (log2 > 1) inmetabolite levels comparedwith untreated controls in at least one of the treated samples. Compounds are color-coded
based on peak activity as shown in Figure 6.Metabolite data for chloroquine, DSM265,MMV000248,MMV006455,MMV019017, and KAE609were sourced from
(Allman et al., 2016). Data for all other 27 compounds were generated in this study. ATQ, atovaquone; Cmpd, compound; CQ, chloroquine; DHA, dihy-
droartemisinin; FQ, ferroquine; LMF, lumefantrine; MB,methylene blue; mETC,mitochondrial electron transport chain; MQ,mefloquine; NQ, naphthoquine; PPQ,
piperaquine.
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relationship to the primary resistance determinant PfMDR1
(located on the membrane of the digestive vacuole) suggested
that mefloquine acts primarily outside the digestive vacuole
(Veiga et al., 2016). The difference in mode of action between
mefloquine and chloroquine is also reflected in their stage spec-
ificity and metabolomics profiles, with mefloquine showing peak
activity only in trophozoites and clustering separately from other
compounds affecting hemoglobin catabolism (Figure 7). These
data further support the notion that the target of mefloquine is
presumably located outside of the digestive vacuole, affecting
the parasite in ways that could not be detected by our metabo-
lomics study.
The clinical antimalarial lumefantrine displayed peak activity
during both rings and trophozoites, similar to chloroquine and pi-
peraquine but different from the trophozoite-only peak activity of
mefloquine. Metabolically, lumefantrine induced minor peptide
increases and clustered with GNF-Pf-5660, which is known to
affect hemoglobin uptake without directly targeting hemozoin
formation (Vanaerschot et al., 2017). The different stage speci-
ficity and metabolic profiles between lumefantrine and meflo-
quine suggest distinct mode of actions, despite PfMDR1 being
a determinant of low-level resistance to both (Eastman and Fi-
dock, 2009).
Methylene blue is known to act as a redox cycler and is used
clinically to treat methemoglobinemia via its reduction of Fe3+ to
Fe2+ (Blank et al., 2012). Methylene blue also binds hematin (a
precursor of hemozoin crystals) at low micromolar concentra-
tions in vitro (Blank et al., 2012). Our finding of similar stage spec-
ificity and metabolomic profiles between methylene blue and
piperaquine suggest that both could affect heme detoxification
and hemozoin formation, albeit via different mechanisms. Meth-
ylene blue potentially causes a reduction of Fe3+, whereas
piperaquine is presumed to bind Fe3+-heme and prevent its
incorporation into chemically inert hemozoin (Dhingra et al.,
2017). Methylene blue, in contrast to piperaquine, is also potent
against mature gametocytes that are not thought to degrade he-
moglobin (Adjalley et al., 2011), implying an additional mode of
action for methylene blue that might affect additional redox
cycling agents such as NADPH levels (Siciliano et al., 2017).
Interestingly, ferroquine and naphthoquine, which are both
chloroquine derivatives that are currently part of artemisinin-
based combination therapies under clinical trials (Isba et al.,
2015; Supan et al., 2017), shared a unique stage specificity
profile showing peak activity during early rings and a gradual in-
crease of IC50
8h values through to schizonts (Figure 2). Ferro-
quine has hemozoin inhibitory activity similar to chloroquine
and has been shown to induce the formation of hydroxyl radicals
via the Fenton reaction, leading to lipid peroxidation and exacer-
bating oxidative stress in the parasite (Atamna and Ginsburg,
1993; Chavain et al., 2008; Dubar et al., 2008). This additional
mode of action might contribute to the unique stage-specific
profile of ferroquine action. The mode of action of naphthoquine
is less understood. Even though parasites exposed to naphtho-
quine and ferroquine did not reveal major changes in the levels of
detected metabolites thus causing them to cluster in the low fold
change metabolic group (Figure 7), their shared and distinctive
stage specificity profiles suggest a common target or pathway.
Compounds with peak activity during ring stages are highly
desired. In our assays, naphthoquine, ferroquine, and WLL-vs
showed peak activity specifically during ring stages, whereas
chloroquine, piperaquine, methylene blue, dihydroartemisinin,
lumefantrine, GNF-Pf-5660, MMV022224, and MMV668311
showed peak activity in rings and trophozoites. This diversity
among ring-active compounds suggests the presence of multi-
ple druggable processes in rings, despite this stage being
considered less metabolically active (Allman et al., 2016) than
trophozoites. One such process involves the proteasome, since
the ring-active compound WLL-vs specifically binds to and in-
hibits the b2 and b5 subunits of the Pf 26S proteasome (Li
et al., 2016; Stokes et al., 2019). Other processes that appear
to begin early in rings include hemoglobin endocytosis and
catabolism (Elliott et al., 2008; Vanaerschot et al., 2017; Xie
et al., 2016).
We note that WLL-vs, included in our study, is a covalent
binder of the Pf 26S proteasome inhibitor, meaning that wash-
out protocols would have little effect on its irreversible mode of
action. Previous studies on Plasmodium have shown that
mRNA transcripts are produced in a ‘‘just-in-time’’ fashion, i.e.,
when they are needed for the parasite’s development (Painter
et al., 2018). This would suggest that the chances of falsely de-
tecting early stage activity are minimal. However, a lingering
effect after drug wash-out could theoretically result in overesti-
mating compound activity during later stages. For this reason,
we have included five different time points at which compound
exposure was started, followed by drug wash-outs, to minimize
compound carry over. This approach was validated with our
WLL-vs data, which showed lower IC50
8h values in rings
compared with trophozoites and schizonts (Figure 2).
An established high-priority mode of action is inhibition of
mitochondrial functions, targeting either DHODH (DSM265) or
CytBC1 (atovaquone) (Goodman et al., 2017) (Figure 5A). Both,
however, yield resistance at low inocula, which in patients
translates into an increased risk of treatment failure using
these classes of inhibitors (Llanos-Cuentas et al., 2018; Musset
et al., 2007). The experimental compounds MMV000787,
MMV021735, and MMV030666 showed peak activity in late tro-
phozoites, albeit with incomplete killing, and shared the same
distinct metabolic profile of increased dihydroorotate and N-car-
bamoyl-L-aspartate levels and decreased orotidine 5-P levels
(Figure 7; Table S4) that is characteristic for DHODH andCytBC1
inhibition (Allman et al., 2016). Interestingly, selections with these
former compounds failed to yield resistant parasites, even at
high inocula of 5 3 108 parasites. They also did not show the
biphasic curves observed for atovaquone and DSM265. These
data raise the possibility that inhibition of mitochondrial path-
ways might be achievable through mode of actions that are
distinct from DHODH and CytBC1 and that are less prone to
acquisition of resistance. In addition to the metabolic signature
of mitochondrial inhibition, MMV030666 also induced decreased
peptide levels (Table S4), causing it to metabolically cluster with
compounds inhibiting hemoglobin catabolism (Figure 7). How
ever, MMV030666 still maintained a late trophozoite stage-spe-
cific activity profile similar to that of DSM265 and atovaquone but
distinct from the overall trophozoite or ring plus trophozoite peak
activity profiles usually observed for the majority of compounds
with a hemoglobin catabolism metabolic signature (Figures 4, 5,
and 7; Table S4). Cell morphological analysis of MMV030666-
exposed parasites (Figure S4) identified late trophozoites as
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the most sensitive intra-erythrocytic stage, consistent with mito-
chondrial inhibition, but also showed a bloated digestive vacuole
that is characteristic for inhibitors of hemoglobin catabolism
(Ross et al., 2018).
Most hits that clustered within the hemoglobin catabolism
group, characterized by decreased peptide levels (Allman et al.,
2016), showed peak activity in trophozoites (MMV027496,
MMV019555, MMV000248, MMV006455, MMV007181, and
MMV000442). The exceptions were GNF-Pf-5660 (Vanaerschot
et al., 2017), lumefantrine, and MMV665794, which showed
peak activity against rings and trophozoites. This observation,
plus additional metabolic changes induced byMMV019555, high-
lights the potential diversity in mode of actions among com-
pounds showing hemoglobin catabolism perturbation.
Among all compounds tested, MMV022224 was unique
both in its metabolomic fingerprint and its stage specificity.
Exposure to MMV022224 caused increased peptide levels
and only this compound showed activity exclusively in rings
and trophozoites but not in schizonts. Peptide accumulation
may suggest a metabolic disruption further downstream
in the hemoglobin catabolism pathway, possibly of an amino-
peptidase or transporter. These unique profiles highlight
MMV022224 as an attractive hit from a discovery and develop-
ment perspective.
It is important to note that the metabolomics experiments in
this studywere exploratory in nature, involving one to two biolog-
ical replicates to screen for known and novel candidate mode of
actions within a large set of compounds. Once compounds are
selected and prioritized for further discovery or development
studies, these metabolomics data should be complemented
with targeted in-depth follow-up studies to validate candidate
targets and mode of actions as demonstrated recently for a
new class of pantothenamides (Schalwijk et al., 2019).
The asexual blood stage susceptibility profiles of compounds
may also help determine whether a protein is a target or solely a
resistancemechanism. Resistance selections withMMV675939,
MMV665939, and MMV020746 all identified SNPs or copy-
number variations in the ABC transporter I family member 1,
also known as ABCI3 (PF3D7_0319700) (Cowell et al., 2018).
MMV675939 was most active on early and late trophozoites
with IC50
8h values that were only 2-fold higher than the IC50
72h
value, while MMV020746 and MMV665939 showed IC50
8h
values that were >28-fold higher than the IC50
72h (Table
S1). This contrast between the timing of peak activity for
MMV675939 and the two other compounds suggests that they
have different modes of actions and that ABCI3 is solely a resis-
tance mediator and not the target.
Asexual blood stage susceptibility profiling may also help pri-
oritize screening hits. Compounds with potent IC50
8h values
across all stages are of particular interest for further develop-
ment as such activity profiles might compensate for a faster
clearance or other pharmacokinetic-related issues that reduce
in vivo exposure time. Dihydroartemisinin and piperaquine, two
first-line antimalarial drugs, showed activity on all stages with
IC50
8h values at the most susceptible stages that were within
2-fold of their IC50
72h values (Table S1). Chloroquine, mefloquine,




8h values still <300 nM (Table S1). Based on these pa-
rameters, ferroquine, WLL-vs, and GNF-PF-5660 represent
promising antimalarial scaffolds. WLL-vs is of particular interest
given its selectivity for the parasite proteasome and the fact that
resistance is rare and low-grade (Li et al., 2016; Stokes et al.,
2019; Yoo et al., 2018). Ferroquine has shown promising efficacy
in phase II trials (Supan et al., 2017) and our assays indicated a
unique ring-active profile that underscores its potential. With
GNF-Pf-5660, chemical derivatization efforts are underway to
improve its partial in vivo efficacy, established in rodent malaria
models (Vanaerschot et al., 2017).
Compounds that show IC50
8h values orders of magnitude
larger than IC50
72h values are potentially of less interest as these
may have multiple mode of actions throughout intra-erythrocytic
development and/or require longer exposures to achieve full
killing. In addition, such a profile indicates that the short expo-
sures usually applied for metabolomics will likely yield a less
informative response. None of the current clinical or advanced
candidate antimalarials showed this profile, suggesting that
this is indeed a good de-prioritization criterion for further devel-
opment. Examples of experimental compounds with such an
unfavorable profile in our dataset were MMV022478 and
MMV019017 (Figure 4), and MMV665939 and MMV020746,
which showed IC50
8h values >10 mM at all stages (data not
shown) (Table S1).
MMV000442, MMV006455, MMV007181, and MMV665971
showed a peculiar profile in early and late ring stages, with initial
growth inhibition at lower compound concentrations that re-
verses to less inhibition at higher concentrations (Figures 3 and
4). Solubility assays with MMV0004442, MMV006455, and
MMV665791 indicated that these compounds have an aqueous
solubility >100 mM, indicating that these survival curves are not
due to solubility issues. This phenomenon has been observed
in other chemical series and can at times be overcome through
lead optimization (Le Manach et al., 2018). Despite their undesir-
able dose-response curves, these compounds might therefore
still prove valuable as starting points for drug discovery efforts.
The asexual blood stage specificity profiles can also inform the
selection of partner drugs for combination therapies. Ideally,
combinations would target all different asexual blood stages.
As an example, schizont-specific compounds could be part-
nered with compounds that target rings and trophozoites. These
profiles can also be used to devise strategies to delay the
emergence of resistance. For example, the late trophozoite-
active compound DSM265 could be combined with another
compound with a broader activity profile including late tropho-
zoite to delay the emergence of DSM265 resistance (Llanos-
Cuentas et al., 2018).
In summary, integrating investigations into antimalarial stage-
specific mode of actions including metabolic perturbations into
drug discovery and development programs should benefit
ongoing efforts to develop new medicines to counter the spread
of antimalarial multidrug resistance, as part of the mission to
eliminate this disease.
SIGNIFICANCE
With the increasing spread of Plasmodium falciparum resis-
tance to artemisinins and their partner drugs, the develop-
ment of antimalarials with new modes of actions is more
critical than ever. High-throughput screens are able to
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identify potent chemical scaffolds, but not knowing their
target often hampers their further development. Malaria
drug discovery pipelines would thus greatly benefit from
new assays that interrogate the mode of action and activity
profile of screening hits. We designed an approach that pro-
vides more resolution into the different modes of action of
clinical and experimental antimalarials by identifying the
specific moment of asexual blood stage development
against which these compounds are most active and
combining this with ametabolomics assessment of pathway
perturbations. This identified several stage specificity pro-
files that correlated well with inhibition of particular meta-
bolic pathways. Interestingly, we also identified compounds
that act on similar pathways albeit through different targets.
Aside from generating insights into the tested clinical anti-
malarials, this approach also offered a rationale for the prior-
itization of experimental compounds. Our study identified
several hits from the Malaria box and the Malaria Drug
Accelerator consortium that showed promising antimalarial
profiles for further development, especially in the context of
combination therapies. Importantly, this approach can also
be adopted for other pathogens that undergomultiple differ-
entiation steps within their host.
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LEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Manu
Vanaerschot (manu.vanaerschot@gmail.com). Please note that availability of experimental compounds may be restricted and might
require resynthesis. All chemical structures as well as SMILES for each compound are available in Figures S1 and S2 and Table S2.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
The Pf parasites used in this study were cultured in human O+ blood (sex of donor unknown) at 3% hematocrit in RPMI-1640 media
supplementedwith 50 mMhypoxanthine, 2 g L-1 sodiumbicarbonate, 2mML-glutamine, 25mMHEPES, 0.5%AlbuMAXII (Invitrogen)
and 10 mg mL-1 gentamycin in 5% O2, 5% CO2 and 90% N2 at 37
C. The 3D7-A10 Pf line is a clone of the 3D7 line received from the
Goldberg lab at Washington State University in St. Louis. The 3D7-MR4 line was obtained from the Malaria Research and Reference
Reagent Resource Center (MR4, Cat#MRA-102). The Dd2-B2 Pf line is a clone obtained by limited dilution from the Dd2 line provided
by Dr. Thomas Wellems (NIAID, NIH).
METHOD DETAILS
Stage Specificity Assay
Standard asexual blood stage susceptibility results were collected by exposing asynchronous 3D7-A10 parasite cultures to 10
different concentrations plus no-compound controls for 72 hr. To determine the specific asexual blood stage at which the com-
pounds are active, schizonts were magnetically purified using MACS LD columns (Miltenyi Biotec) from cultures that had been
repeatedly synchronized with 5% sorbitol. After a 3hr incubation at 2% hematocrit to allow re-invasion, cultures were again sorbi-
tol-synchronized to obtain a pure ring-stage culture (time = 0 hr). These parasites were then plated in five 96-well plates and exposed
to compounds (SMILES and origin listed in Table S2, structures shown in Figures S1 and S2) as early rings (0-8 hr), late rings (8-16 hr),
early trophozoites (16-24 hr), late trophozoites (24-32 hr) or schizonts (32-40 hr). Incubation times were adjusted to the 40 hr asexual
blood stage cycle of the 3D7-A10 parasite line. Synchronicity of the cultures was confirmed by imaging on average 83 parasites per
time point in control conditions. Compounds were removed through three rounds of washing including two plate changes in 37C
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prewarmed culture media after each exposure. All pipetting steps to expose and wash parasites were performed using a Tecan
Freedom Evo 100 for increased throughput and accuracy. Each group of plates per timepoint were placed in a separate humidified
chamber to avoid any delay in growth rate due to temperature variations. For the stage specificity assay, growth inhibition was as-
sessed at the 60 hr time point at which parasites had expanded, reinvaded new RBCs, and developed into the trophozoite stage that
allows straight-forward quantification by flow cytometry. This is very similar to the standard 72 hr assay in which parasites are not
synchronized, but also allowed to reinvade and develop further for another half life cycle. Parasite survival for both the 72 hr and
stage-specific 8 hr exposures was assessed by SYBR Green and MitoTracker Deep Red FM staining (Life Technologies) and sub-
sequent flow-cytometric analysis (Accuri C6, BD Biosciences) (Ekland et al., 2011). IC50 values were derived from growth inhibition
data using nonlinear regression (Prism 7, GraphPad). All asexual blood stage assays were repeated on at least three independent
occasions with two technical replicates.
Culturing for Metabolomics
3D7-MR4 parasites were cultured at 50 ml volumes and 2% hematocrit as described elsewhere (Allman et al., 2016). Cultures were
kept at the appropriate temperature and gas mixture in incubators between media exchange, culture division, and synchronization.
Synchronization was achieved via 5% sorbitol. All reagents and experimental spaces were mycoplasma-free, and reagents passed
through 0.2 mm liquid filters when possible prior to use.
Metabolomics
Hydrophilic metabolite changes in response to compound exposure were profiled as previously described (Allman et al., 2016).
Treatments were performed on 1 3 108 MACS-purified, synchronized trophozoite parasite-infected RBCs (24-36 hr post invasion)
in 5 mL RPMI. Compounds were added at a concentration of 10 3 IC50
72hr and incubated for 2.5 hr. All treatment conditions
were performed as technical triplicates and included an untreated control. Subsequently, PBSwashes were performed, and infected
RBCs were extracted with 90% methanol containing 0.5 mM 13C15N-labelled aspartate as an internal standard, then dried under
nitrogen and stored at -80C. Process blanks were generated at the time of extraction in technical triplicates. Samples were then
resuspended in high-performance liquid chromatography (HPLC) grade water containing 1 mM chlorpropamide as an additional in-
ternal standard and analyzed by ultra-high-performance liquid chromatography mass spectrometry UHPLC-MS as described (All-
man et al., 2016).
Targeted Analysis
Following negative ionization analysis of hydrophilic extracts on a Thermo Exactive Plus Orbitrap, sample data were converted and
transferred for analysis. Targeted peak picking from a curated list of 298metabolites was achieved using el-MAVEN software (https://
elucidatainc.github.io/ElMaven/ (Agrawal et al., 2019)), followed by normalization and analysis via RStudio (http://www.rstudio.com/)
and Metaboanalyst (https://www.metaboanalyst.ca/ (Chong et al., 2018)). Data were visualized using the Hyperspec (http://
hyperspec.r-forge.r-project.org) and Suprahex R (Fang and Gough, 2014) scripting packages in RStudio. Hierarchical clustering
of the metabolic profiles to identify related metabolic signatures was performed using the Ward method, based on the Pearson cor-
relation coefficients, by the Hyperspec R integrated heatmap function.
Resistance Selections
Attempts to obtain parasites resistant to MMV030666, MMV000787 and MMV021735 were performed using either single step
(continuous) or ramping selection protocols as described elsewhere (Cowell et al., 2018). For single step selections, parasites are
continuously exposed to relatively high concentrations of the compound of interest (usually 3 3 IC50) with culture media and
RBCs being regularly refreshed until actively growing parasites are again observed. Cultures were monitored for minimum
70 days after start of exposure. For ramping selections, parasites are exposed at low compound concentrations (usually 1 3 IC50
or lower) and parasite growth is continuously monitored. When parasites seem to have adapted to the pressure, compound concen-
trations are gradually increased to adapt parasites to even higher levels of compound. Standard IC50
72hr assays were performed on
recrudesced parasites from single step selections, if any, and on parasites resulting from ramping selections.
Solubility Assay
The aqueous solubility of MMV007181, MMV000442 and MMV006455 was determined at a single concentration of 500 mM because
of compound scarcity. The protocol usedwas adapted fromMillipore Corporation’s ‘‘MultiScreenSolubility Filter Plate’’ application
note. Dihydroartemisinin, chloroquine and piperaquine were used as controls. Briefly, compounds were first dissolved in DMSO at
10mM. Theywere then added to 13PBS (pH 7.4) at a 1:20 ratio in 1.5ml tubes andmixed on a shaker (100 rpm) at room temperature
for 1.5 hr. They were then filtered using Target2 regenerated cellulose 0.2 mM filters (Thermal Scientific, part number F2500-8) to re-
move any precipitate. 160 ml of the filtrate was dispensed into flat-bottomed 96-well culture plates and diluted with 40 ml/well aceto-
nitrile. The plate was then placed on a shaker (100 rpm) at room temperature for 10min. After mixing, the filtrate was analyzed using a
Spectramax 340PC (Molecular Devices) at 280, 300, 320, 340, 360 and 800 nm. Standards were made by adding compounds into
standards buffer (80:20 1 3 PBS: acetonitrile, pH 7.4) at a 1:25 ratio. The mixtures were allowed to mix on a shaker (100 rpm) for
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10 min at room temperature and analyzed at the same six wavelengths as mentioned above. The aqueous solubility of compounds
was then determined by calculating the ratio of absorbances between the filtrate and the standard using the formula below:
ðPAU at 280; 300; 320; 340; 360 nmÞ  ðAU at 800 nmÞ Filtrate
ðPAU at 280; 300; 320; 340; 360 nmÞ  ðAU at 800 nmÞ Standard
If the ratio isz 1, a compound’s aqueous solubility isR 500 mM. Ratios < 1.0 and > 0.5 indicate a solubility between 100 mM and
500 mM, while ratios % 0.5 indicate a solubility % 100 mM.
QUANTIFICATION AND STATISTICAL ANALYSIS
All details of the stage specificity experiments, including the number of biological (n), can be found in Table S1. The standard error of
the mean (SEM) was used to report error values for means based on multiple independent repeats. Details on the number of repeats
of the metabolomics study can be found in the legend of Table S4. This study did not perform any other statistical methods on
the data.
DATA AND CODE AVAILABILITY
The published article includes all datasets generated in this study. The IC50 data and survival curves are available in Table S1 and
Figures 1, 2, 3, 4, and 5. Metabolomics data is available in Table S4.
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Table S1 (related to Figures 1–6). Asexual blood stage-specific IC50
8h data in nM for the tested antimalarials.
Dihydroartemisinin 1.5 0.1 3 2.4 0.1 3 2.4 0.4 3 3.9 0.2 3 11.6 1.3 3 1.0 0.1 4 Rings + Trophs 1.5
Chloroquine 17.8 5.5 4 18.6 2.5 3 17.4 3.5 3 30.1 6.3 3 60.3 13.4 3 5.9 0.8 3 Rings + Trophs 2.9
Mefloquine 258 106 3 147 74 3 28.8 7.0 3 29.5 6.9 3 138 39 3 9.8 1.0 3 Trophs 3.0
Lumefantrine 15.4 4.0 3 15.8 3.5 3 19.54 1.6 3 22.3 2.0 3 81.0 32.5 3 1.3 0.0 3 Rings + Trophs 11.6
Piperaquine 26.2 1.1 3 46.3 13.1 3 27.4 3.3 3 32.9 1.1 3 67.0 9.6 3 15.4 2.3 4 Rings + Trophs 1.7
Ferroquine 4.9 0.3 3 10.9 1.7 3 23.2 2.4 3 36.8 3.3 3 49.3 6.2 3 3.5 0.4 4 Rings 1.4
Methylene blue 3.2 0.3 3 13.3 2.7 3 5.9 0.4 3 8.3 2.0 3 64.8 17.8 3 1.8 0.1 4 Rings + Trophs 1.8
KAI407 - shift 1 - - - - - - - - - 161 44.0 3 - - - - - - - 3.9
KAI407 - shift 2 16263 904 2 14021 923 3 5139 1727 3 13386 354 2 46.2 0.6 3 11.8 1.0 3 Schizonts -
AN3661 > 1.25 μM - 3 > 1.25 μM - 3 > 1.25 μM - 3 138 39 3 400 34 3 35.6 3.6 3 Late Trophs 3.9
KAE609 > 1.25 μM - 3 > 1.25 μM - 3 3.2 0.6 3 1.1 0.2 3 1.2 0.1 3 0.73 0.05 4 Trophs + Schizonts 1.5
WLL-vs 23.7 2.6 3 29.4 4.4 3 57.6 3.1 3 47.1 3.1 3 50.1 5.7 3 7.2 0.8 3 Rings 3.3
DSM265 - shift 1 - - - - - - 10.2 2.2 3 7.7 0.9 3 19.2 2.3 3 3.8 0.1 3 Late Trophs 2.0
DSM265 - shift 2 4821 1605 3 1493 308 3 1481 240 3 - - - > 25 μM - - - - - - -
Atovaquone - shift 1 - - - - - - 0.68 0.06 3 3.7 0.2 3 7.4 1.3 3 1.1 0.1 3 Late Trophs 3.3
Atovaquone - shift 2 553 228 3 324 45 3 619 132 3 - - 3 > 25 μM - 3 - - - - -
Fosmidomycin > 10 μM - 3 > 10 μM - 3 1983 665 3 1993 117 3 > 10 μM - 3 405 8 3 Trophs 4.9
GNF-Pf-5660 119 30 3 238 57 3 108 6 3 79.3 10.8 3 290 50 3 4.4 0.2 3 Rings + Trophs 18.0
MMV665794 369 101 3 590 177 3 210 20 3 165 10 3 203 8 3 91.3 5.2 4 Trophs + Schizonts 1.8
Naphtoquine 4.2 1.8 3 8.1 0.4 3 19.5 2.9 3 29.2 3.1 3 42.8 8.4 3 3.2 0.4 4 Rings 1.3
MMV000442 > 8 μΜ - 3 > 8 μΜ - 3 176 11 3 197 22 3 503 48 3 37.2 3.1 3 Trophs 4.7
MMV675939 1170 277 3 268 84 3 62.9 29.9 3 146 54 3 1647 45 3 30.8 4.4 5 Trophs 2.0
MMV085071 893 78 3 492 122 3 61.1 0.1 3 81.4 2.8 3 254 47 3 105 11 3 Trophs 0.6
MMV668311 140 39 3 97.7 4.3 3 68.9 11.9 3 122 26 3 382 79 3 63.5 1.7 3 Rings + Trophs 1.1
MMV020746 > 25 μM - 2 > 25 μM - 2 12587 1681 2 > 25 μM - 2 > 25 μM - 2 56.8 6.6 4 All stages > 10 μM 221.5
MMV667491 2264 349 3 1270 92 3 521 28 3 731 50 3 842 108 3 243 35 4 Trophs + Schizonts 2.1
MMV006455 > 12.5 μM - 3 > 12.5 μM - 3 441 10 3 450 46 3 933 142 3 439 46 4 Trophs 1.0
MMV022478 7628 202 2 4870 353 2 2132 252 2 2529 353 2 3370 269 2 11.1 0.8 3 Trophs + Schizonts 192.4
MMV007181 > 25 μM - 3 > 25 μM - 3 253 27 3 274 16 3 570 107 3 84.9 8.9 3 Trophs 3.0
MMV665971 > 25 μM - 3 > 25 μM - 3 496 51 3 485 26 3 523 29 3 185 9 3 Trophs + Schizonts 2.6
MMV665939 17011 2420 3 22853 5330 3 13476 4752 3 39017 13066 3 54384 14265 3 478 49 4 All stages > 10 μM 28.2
MMV019017 8418 1862 2 8663 2298 3 1338 133 3 1708 116 3 3060 229 3 306 12 3 Trophs + Schizonts 4.4
MMV000248 n.d. n.d. 0 6744 - 1 411 - 1 376 - 1 754 - 1 103 14 4 Trophs 3.7
MMV021735 > 25 μM - 3 > 25 μM - 3 5422 1392 3 234 12 3 5281 622 3 232 11 4 Late Trophs 1.0
MMV022224 838 123 3 845 152 3 542 39 3 752 58 3 2486 472 3 199 31 5 Rings + Trophs 2.7
MMV027496 2760 529 3 878 130 3 168 26 3 199 9 3 4339 545 3 89.7 7.9 3 Trophs 1.9
MMV019555 755 159 3 788 221 3 81.4 1.6 3 110 20 3 349 66 3 33.3 1.8 3 Trophs 2.4
MMV030666 10264 3053 3 11440 861 3 5124 506 3 858 29 3 4191 307 3 462 18 4 Late Trophs 1.9











Shift 1 and shift 2 indicate the two half-maximal inhibitory concentrations for biphasic dose response curves.  SEM: standard error of the mean; n: number of biological repeats; - : no data; IC50
8h: IC50 based on 8-h exposure; IC50
72h: 
IC50 based on 72-h exposure.











Dihydroartemisinin (DHA) C[C@@H]1CC[C@H]2[C@H]([C@H](O[C@H]3[C@@]24[C@H]1CCC(O3)(OO4)C)O)C - - -
Chloroquine (CQ) CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl β-hematina - -
Mefloquine (MFQ) c1cc2c(cc(nc2c(c1)C(F)(F)F)C(F)(F)F)[C@@H]([C@H]3CCCCN3)O - - -
Lumefantrine (LMF) CCCCN(CCCC)CC(C1=C2C3=C(C=C(C=C3)Cl)C(=CC4=CC=C(C=C4)Cl)C2=CC(=C1)Cl)O - - -
Piperaquine (PPQ) c1cc2c(ccnc2cc1Cl)N3CCN(CC3)CCCN4CCN(CC4)c5ccnc6c5ccc(c6)Cl β-hematinb - -
Ferroquine (FQ) CN(C)CC1=C(C=[C-]C1)CNC2=C3C=CC(=CC3=NC=C2)Cl.C1C=CC=[C-]1.[Fe+2] β-hematinc,d - -
Methylene blue (MB) CN(C)C1=CC2=C(C=C1)N=C3C=CC(=[N+](C)C)C=C3S2.[Cl-] β-hematine - -
KAI407 O=C(N(C)C1=CC=C(C=C1)C#N)C2=CN3C(C=N2)=NC=C3C4=CC=C(C=C4)C(F)(F)F PI4Kf - -
AN3661 OB1C2=C(CCC(O)=O)C=CC=C2CO1 CPSFg - -
KAE609 ClC1=C(F)C=C2C(NC3=C2C[C@H](C)N[C@@]34C(CC5=C4C=C(Cl)C=C5)=O)=C1 ATP4h - -
WLL-vs CC(C)C[C@@H](/C=C/S(=O)(=O)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)CN3CCOCC3 Proteasomei,j - -
DSM265 FS(F)(F)(F)(C1=CC=C(NC2=CC(C)=NC3=NC(C(F)(F)C)=NN23)C=C1)F DHODHk - -
Atovaquone (ATQ) O=C1C([C@@H]2CC[C@@H](C3=CC=C(Cl)C=C3)CC2)=C(O)C(C4=CC=CC=C41)=O CYTBl - -
Fosmidomycin C(CN(C=O)O)CP(=O)(O)O DXRm - -
GNF-Pf-5660 CCOC(=O)C1=C(C)NC2=C(C1C3=CC=CC=C3Cl)C(=O)CC(C2)C4=CC=C(OC)C(OC)=C4 *n - -
Naphthoquine (NQ) CC(C)(C)NCc1cc(c2c(c1O)CCCC2)Nc3ccnc4c3ccc(c4)Cl - - MMV000017
MMV665794 FC(F)(F)C1=CC(NC2=C(NC3=CC(=CC=C3)C(F)(F)F)N=C3C=CC=CC3=N2)=CC=C1 - MMV Malaria Box -
MMV000442 CC(C)(C)c1ccc2OCN(Cc3ccc(Cl)cc3)Cc2c1 - MMV Malaria Box -
MMV675939 FC(F)(F)C1=CC=C(NC2=CC(NC(C3=CC(C(F)(F)F)=CC=C3)=N4)=C4C=N2)N=C1 - Literatureo -
MMV085071 COc1cncc(c1)-c1cncc(n1)N1CCN(CC1)c1ccncc1 - MMV Pathogen Box -
MMV668311 CNc1nc(NCCCN(C)C)c2sc(cc2n1)c3cccc(c3)C(F)(F)F - Literaturep -
MMV020746 Cc1ccc(Oc2ncccc2C(=O)Nc2cccc3cccnc23)c(C)c1 - Literaturep TCMDC-125499
MMV667491 CN(C)CCCn1cnc2c(c1=N)C(c3ccc4ccccc4c3O2)c5ccc(cc5)OC - MMV Malaria Box -
MMV006455 CCCN(CCC)CC(O)COC1=C(C=CC=C1)C(=O)NC1=CC=CC=C1 - MMV Malaria Box -
MMV022478 Clc1cccc(c1)-c1cnn2ccc(nc12)C(=O)Nc1ccc(cc1)N1CCNCC1.OC(C(F)(F)F)=O - MMV Pathogen Box -
MMV007181 CC1=C2C=CC(O)=CC2=NC(NC2=CC=C(OCC3=CC=CC=C3)C=C2)=C1 - MMV Malaria Box -
MMV665971 CCOC(=O)C1=C(C)N=c2s\c(=C/c3cc(Cl)ccc3O)c(=O)n2C1c1ccc(OC)cc1 - MMV Malaria Box -
MMV665939 FC1=CC=C(C=C1)C(=O)NC1=C(SC=C1)C(=O)NC1CCCCC1 - MMV Malaria Box -
MMV019017 COCCNCC(O)CN1C2=CC=C(Cl)C=C2C2=C1C=CC(Cl)=C2 - MMV Malaria Box -
MMV000248 Cl.CCN(CC)CCn1c2ccccc2n(CC(O)c2ccc(Cl)c(Cl)c2)c1=N - MMV Malaria Box -
MMV021735 CCCCCCCN(CC1=CC=C(OC(C)(C)C(=O)OCC)C=C1)C(=O)NC1=CC=C(Cl)C=C1OCC - Literaturep TCMDC-131919
MMV022224 [O-]C(=O)C(F)(F)F.CN(C)CC1=CC=C(C=C1)C1=CC2=C(N1)N=CC=C2C1=CC=C(CN(C)C)C=C1 - Literaturep TCMDC-132409
MMV027496 COC1=C(OCCN(C)C)C=CC(=C1)C1=NC(=C(N1)C1=CC=CC=C1)C1=CC=CC=C1 - Literaturep TCMDC-137716
MMV019555 Cl.C(CCCNc1c2CCCCc2nc2ccccc12)CCNc1c2CCCCc2nc2ccccc12 - MMV Malaria Box TCMDC-124183
MMV030666 CC(C)(C)OC(=O)N1CCN(CC1)C1=CC=CC=C1NC(=O)C1=C(OC2=CC=C(F)C=C2)C(=CC=C1)C(F)(F)F - Literaturep TCMDC-140951
MMV000787 CCCOCC1=C2C=CC=NC2=C(O)C(CN2CCN(CC2)C2=CC(Cl)=CC=C2)=C1 - MMV Malaria Box -
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Table S3 (related to Figure 4). Assessment of compound solubility by UV/vis spectroscopy.
280 300 320 340 360 800
DHA fil. 2.351 0.462 0.250 0.179 0.124 0.041
DHA std. 2.314 0.456 0.244 0.173 0.120 0.042
Chloroquine fil. 2.637 1.170 2.155 2.075 0.203 0.042
Chloroquine std. 2.747 1.331 2.562 2.178 0.204 0.041
Piperaquine fil. 2.322 0.473 0.269 0.189 0.129 0.041
Piperaquine std. 2.694 0.822 0.646 0.555 0.462 0.304
MMV007181 fil. 2.346 0.470 0.259 0.194 0.139 0.042
MMV007181 std. 2.677 0.754 0.534 0.551 0.508 0.131
MMV000442 fil. 2.517 0.606 0.380 0.310 0.248 0.086
MMV000442 std. 2.754 0.898 0.711 0.660 0.619 0.274
MMV006455 fil. 2.810 0.904 0.336 0.186 0.130 0.041
MMV006455 std. 2.826 0.928 0.329 0.175 0.120 0.041
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Figure S1 (related to Figures 1–6). Structures of the tested antimalarials, part 1. References on mode of action can be 





























































































































































































Figure S2 (related to Figures 1–6). Structures of the tested antimalarials, part 2. References on mode of action can be 










































































































































































Figure S3 (related to Figure 6). Overall activity profile of compounds. Overall activity is defined as the stages with IC508h 
values < 1 μM. Fosmidomycin, MMV000787, MMV019017, MMV020746, MMV022478 and MMV665939 are not depicted, 
as all stages showed IC508hr values > 1 μM. MMV006455, MMV000442, MMV007181 and MMV665971 are omitted from 
panel A due to incomplete killing at individual stages. DHA: dihydroartemisinin; CQ: chloroquine; PPQ: piperaquine; LMF: 








Figure S4 (related to Figure 2 and Figure 4). Microscopical studies confirm the stage specificity profiles of MMV030666 
and MMV022224, using ATQ and CQ as controls. Synchronized parasites were exposed to 3× their lowest IC508h at the 
indicated life stages, and were assessed at the end of each exposure. ATQ: atovaquone, CQ: chloroquine. 
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